Saudi Arabia

The Saudi Food and Drug Authority (SFDA) is the primary national regulatory body responsible for overseeing the registration, licensing, and post-market surveillance of health products in Saudi Arabia, including pharmaceuticals, medical devices, diagnostics, and digital health solutions. Established under the Council of Ministers Resolution No. 1/m dated 2003 and further empowered through the Food and Drug Law issued by Royal Decree No. M/55 in 2005, the SFDA operates through specialized centers such as the Drug Sector, the Medical Devices Sector, and the Food Sector. All health products must undergo formal registration and receive SFDA marketing authorization before they can be commercially distributed or used within the Kingdom. The registration process involves a structured dossier review, risk classification assessment, and conformity evaluation, with timelines varying by product category and risk level.

Applicants seeking SFDA registration are required to appoint a locally licensed Saudi Authorized Representative (SAR) or a registered establishment in the Kingdom to act as the regulatory liaison. Submissions for pharmaceuticals follow the Common Technical Document (CTD) format aligned with International Council for Harmonisation (ICH) guidelines, while medical devices must comply with SFDA medical device technical regulations, which are broadly harmonized with the Global Harmonization Task Force (GHTF) and International Medical Device Regulators Forum (IMDRF) frameworks. The SFDA has accelerated its digital transformation through the GHAD and MDMA online portals, streamlining application submissions and status tracking. Notable recent reforms include the introduction of a reliance pathway that recognizes approvals from stringent regulatory authorities such as the US FDA, EMA, Health Canada, TGA, and PMDA, significantly reducing review timelines for eligible products. Saudi Arabia's Vision 2030 agenda has further driven regulatory modernization, with the SFDA expanding its capacity for in-country Good Manufacturing Practice (GMP) inspections and strengthening pharmacovigilance and post-market surveillance requirements.

Public procurement of health products in Saudi Arabia is primarily coordinated through the Ministry of Health (MOH), which operates the largest network of public hospitals, primary healthcare centers, and specialized facilities across the Kingdom. The National Center for Government Procurement (NCGP), established under the Government Tenders and Procurement Law (Royal Decree No. M/128 of 2019), governs the overarching framework for public tendering, mandating transparency, competition, and value-for-money principles across all government entities. Major procurement of pharmaceuticals and medical supplies is executed through centralized tenders managed by the MOH's General Directorate of Contracts and Procurement, with the Saudi Arabian National Guard Health Affairs (SANGHA), the Ministry of Defense Medical Services, and the National Guard operating as significant independent procurement entities with their own tender processes. The Saudi Health Council plays a coordinating role in setting national health priorities that inform procurement planning, while hospitals affiliated with universities and specialized commissions such as the King Faisal Specialist Hospital and Research Centre conduct their own independent procurement activities.

The private healthcare sector in Saudi Arabia is substantial and growing, encompassing large hospital groups, pharmacy chains, and diagnostic networks that procure health products through direct commercial channels, distributors, and group purchasing arrangements. Private sector procurement is governed by standard commercial contracting practices and does not fall under the Government Tenders and Procurement Law, offering more flexible and faster purchasing cycles. Saudi Arabia does not rely significantly on donor-funded procurement channels such as UNICEF Supply Division, the Global Fund, USAID, or Gavi, as it is an upper-middle-to-high-income country that self-finances its health system. However, the Kingdom actively participates in the Gulf Cooperation Council (GCC) joint procurement program, coordinated through the GCC Pharmaceutical Affairs Committee, which enables pooled tendering for selected medicines and vaccines to achieve favorable pricing. In line with Vision 2030 objectives, the government has introduced local manufacturing preference policies that incentivize in-country production of health products, including pharmaceutical localization initiatives supported by the Saudi Industrial Development Fund (SIDF) and regulatory fast-track pathways for locally manufactured goods, aiming to reduce import dependency and build domestic health industry capacity.